Table 2

Study outcomes
Outcomes TXA Placebo RD RR
(n = 120) (n = 118) [95% CI] [95% CI]
Progressive intracranial haemorrhage (PIH) 21 (18%) 32 (27%) −0.10 0.65
moderate TBI (n = 24) 7 (6%) 17 (14%) [(−0.20)- [0.40-1.05]
severe TBI (n = 20) 9 (8%) 11 (9%) (−0.01)]
indicated neurosurgery 6 (5%) 6 (5%)
Increase in pressure effect* *11 (10%) 12 (11%) −0.01 0.91
[(−0.09) – 0.07] [0.42-1.97]
Improved GCS motor score at 24 hours 37 (31%) 37 (31%) −0.01 0.98
[(−0.12) – 0.11] [0.67-1.44]
Neurosurgical intervention 3 (3%) 0 0.03 ---
[(−0.00) – 0.05] ---
Blood products transfusion 31 (26%) 33 (28%) −0.02 0.92
[(−0.13) – 0.09] [0.61-1.40]
Death 12 (10%) 17 (14%) −0.04 0.69
[(−0.13) – 0.04] [0.35-1.39]
Unfavorable (GOS) outcome 21 (18%) 27 (23%) −0.05 0.76
[(−0.16) – 0.05] [0.46-1.27]
Adverse events
Stroke 0 3 --- ---
Pulmonary embolus 0 0 --- ---
Deep vein thrombosis 0 0 --- ---
Gastrointestinal bleeding 0 1 --- ---

*Denominator for outcomes is 114 for TXA group and 115 for placebo group. This is an analysis based on complete case analysis that is not assumed the missing outcome.

Yutthakasemsunt et al.

Yutthakasemsunt et al. BMC Emergency Medicine 2013 13:20   doi:10.1186/1471-227X-13-20

Open Data